NYSE US 100

NYSE US 100 handeln
19.171,88 PKT -36,58 PKT -0,19 %
finanzen.net zero
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Analysen zu NYSE US 100-Werten

Datum Rating Analyst
11.04.12 Walmart buy Buckingham Research
11.04.12 AT&T equal-weight Barclays Capital
10.04.12 Citigroup overweight Barclays Capital
10.04.12 ConocoPhillips sell UBS AG
10.04.12 Bayer neutral UBS AG
10.04.12 JPMorgan Chase overweight Barclays Capital
10.04.12 Schlumberger overweight Barclays Capital
05.04.12 McDonalds buy Goldman Sachs Group Inc.
05.04.12 IBM neutral Banc of America Securities-Merrill Lynch
05.04.12 Devon Energy buy UBS AG
05.04.12 Chevron neutral Sarasin Research
05.04.12 Bayer buy Sarasin Research
05.04.12 ExxonMobil outperform Macquarie Research
04.04.12 Citigroup buy Nomura
04.04.12 Bank of America neutral Nomura
04.04.12 Pfizer halten Independent Research GmbH
03.04.12 Coca-Cola hold Stifel, Nicolaus & Co., Inc.
03.04.12 Bayer neutral Nomura
03.04.12 Bank of America hold Deutsche Bank Securities
03.04.12 Citigroup buy Deutsche Bank Securities
03.04.12 Schlumberger outperform RBC Capital Markets
03.04.12 HP outperform Sanford C. Bernstein and Co., Inc.
02.04.12 Morgan Stanley neutral UBS AG
02.04.12 JPMorgan Chase buy UBS AG
02.04.12 Goldman Sachs buy UBS AG
02.04.12 Citigroup buy UBS AG
02.04.12 Bank of America neutral UBS AG
02.04.12 Texas Instruments neutral UBS AG
02.04.12 Bayer outperform Cheuvreux SA
30.03.12 Bayer add Commerzbank Corp. & Markets
30.03.12 Coca-Cola kaufen National-Bank AG
30.03.12 McDonalds kaufen Fuchsbriefe
29.03.12 IBM outperform Oppenheimer & Co. Inc.
29.03.12 IBM outperform RBC Capital Markets
29.03.12 Verizon neutral Robert W. Baird & Co. Incorporated
29.03.12 AT&T neutral Robert W. Baird & Co. Incorporated
29.03.12 JPMorgan Chase neutral HSBC
28.03.12 Pfizer buy Goldman Sachs Group Inc.
28.03.12 Bank of America neutral Robert W. Baird & Co. Incorporated
28.03.12 Texas Instruments underperform Exane-BNP Paribas SA